Literature DB >> 15265850

MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis.

Mogens Vestergaard1, Anders Hviid, Kreesten Meldgaard Madsen, Jan Wohlfahrt, Poul Thorsen, Diana Schendel, Mads Melbye, Jørn Olsen.   

Abstract

CONTEXT: The rate of febrile seizures increases following measles, mumps, and rubella (MMR) vaccination but it is unknown whether the rate varies according to personal or family history of seizures, perinatal factors, or socioeconomic status. Furthermore, little is known about the long-term outcome of febrile seizures following vaccination.
OBJECTIVES: To estimate incidence rate ratios (RRs) and risk differences of febrile seizures following MMR vaccination within subgroups of children and to evaluate the clinical outcome of febrile seizures following vaccination. DESIGN, SETTING, AND PARTICIPANTS: A population-based cohort study of all children born in Denmark between January 1, 1991, and December 31, 1998, who were alive at 3 months; 537,171 children were followed up until December 31, 1999, by using data from the Danish Civil Registration System and 4 other national registries. MAIN OUTCOME MEASURES: Incidence of first febrile seizure, recurrent febrile seizures, and subsequent epilepsy.
RESULTS: A total of 439,251 children (82%) received MMR vaccination and 17,986 children developed febrile seizures at least once; 973 of these febrile seizures occurred within 2 weeks of MMR vaccination. The RR of febrile seizures increased during the 2 weeks following MMR vaccination (2.75; 95% confidence interval [CI], 2.55-2.97), and thereafter was close to the observed RR for nonvaccinated children. The RR did not vary significantly in the subgroups of children that had been defined by their family history of seizures, perinatal factors, or socioeconomic status. At 15 to 17 months, the risk difference of febrile seizures within 2 weeks following MMR vaccination was 1.56 per 1000 children overall (95% CI, 1.44-1.68), 3.97 per 1000 (95% CI, 2.90-5.40) for siblings of children with a history of febrile seizures, and 19.47 per 1000 (95% CI, 16.05-23.55) for children with a personal history of febrile seizures. Children with febrile seizures following MMR vaccinations had a slightly increased rate of recurrent febrile seizures (RR, 1.19; 95% CI, 1.01-1.41) but no increased rate of epilepsy (RR, 0.70; 95% CI, 0.33-1.50) compared with children who were nonvaccinated at the time of their first febrile seizure.
CONCLUSIONS: MMR vaccination was associated with a transient increased rate of febrile seizures but the risk difference was small even in high-risk children. The long-term rate of epilepsy was not increased in children who had febrile seizures following vaccination compared with children who had febrile seizures of a different etiology.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265850     DOI: 10.1001/jama.292.3.351

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  43 in total

1.  Temporal data mining for adverse events following immunization in nationwide Danish healthcare databases.

Authors:  Henrik Svanström; Torbjörn Callréus; Anders Hviid
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

2.  A postmarket safety comparison of 2 vaccination strategies for measles, mumps, rubella and varicella in Italy.

Authors:  Silvia Cocchio; Giovanna Zanoni; Roberta Opri; Francesca Russo; Vincenzo Baldo
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

Review 3.  Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009.

Authors:  S Elizabeth Williams; Nicola P Klein; Neal Halsey; Cornelia L Dekker; Roger P Baxter; Colin D Marchant; Philip S LaRussa; Robert C Sparks; Jerome I Tokars; Barbara A Pahud; Laurie Aukes; Kathleen Jakob; Silvia Coronel; Howard Choi; Barbara A Slade; Kathryn M Edwards
Journal:  Vaccine       Date:  2011-07-27       Impact factor: 3.641

4.  Improving vaccine safety through a better understanding of vaccine adverse events.

Authors:  Björn Pasternak; Bjarke Feenstra; Mads Melbye; Anders Hviid
Journal:  Clin Infect Dis       Date:  2015-02-03       Impact factor: 9.079

5.  Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.

Authors:  Lakshmi Sukumaran; Michael M McNeil; Pedro L Moro; Paige W Lewis; Scott K Winiecki; Tom T Shimabukuro
Journal:  Clin Infect Dis       Date:  2015-01-30       Impact factor: 9.079

6.  Efficacy of varicella (VZV) vaccination: an update for the clinician.

Authors:  Lili Wang; Lucy Zhu; Hua Zhu
Journal:  Ther Adv Vaccines       Date:  2016-01-01

Review 7.  Application of pharmacogenomics to vaccines.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Pharmacogenomics       Date:  2009-05       Impact factor: 2.533

Review 8.  Personalized vaccines: the emerging field of vaccinomics.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Expert Opin Biol Ther       Date:  2008-11       Impact factor: 4.388

9.  Knowledge synthesis of benefits and adverse effects of measles vaccination: the Lasbela balance sheet.

Authors:  Robert J Ledogar; John Fleming; Neil Andersson
Journal:  BMC Int Health Hum Rights       Date:  2009-10-14

Review 10.  Role of brain inflammation in epileptogenesis.

Authors:  Jieun Choi; Sookyong Koh
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.